Therapeutic potential of the interleukin-4/interleukin-13 inhibitor dupilumab for treating IgG4-related disease

Rheumatology (Oxford). 2022 May 30;61(6):e151-e153. doi: 10.1093/rheumatology/keab950.

Authors

Isana Nakajima¹, Yoshinori Taniguchi², Hideki Tsuji³, Tomoka Mizobuchi¹, Ken Fukuda¹

Affiliations

¹ Department of Ophthalmology and Visual Science.
² Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University, Nankoku City, Kochi.
³ Department of Ophthalmology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

PMID: 34962989
DOI: 10.1093/rheumatology/keab950

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Immunoglobulin G4-Related Disease* / drug therapy
Interleukin-13*
Interleukin-4

Substances

Antibodies, Monoclonal, Humanized
Interleukin-13
Interleukin-4
dupilumab